← Leaderboards
Victoria Lin Bae-Jump
Univ Of North Carolina Chapel Hill
$4,533,215
Attributed
$5,507,125
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,762,235 · 9
By mechanism
U54$2,505,677 · 2
R37$2,454,372 · 1
R21$1,133,381 · 3
K23$854,365 · 1
T32$664,720 · 1
R03$149,720 · 1
Top collaborators
- Temitope O. Keku2 shared
- Abbie E Smith-Ryan2 shared
- Dhiren R Thakker2 shared
- Bernard E. Weissman2 shared
- William C Zamboni2 shared
- Hazel B Nichols1 shared
- Alisa S Wolberg1 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- William C Zamboni$5,390,027
- Temitope O. Keku$4,871,694
- Michael G Hudgens$22,139,032
- Dhiren R Thakker$1,360,879
- Abbie E Smith-Ryan$689,602
Others in their field
Top investigators on “Endometrial Carcinoma”
- Philip J Disaia · University Of California Irvine$132,718,689
- David Heimbrook · Leidos Biomedical Research, Inc.$57,537,613
- Walter John Curran · Thomas Jefferson University$47,862,860
- Norman Wolmark · Nsabp Foundation, Inc.$21,221,311
- Robert C Park · American College Of Ob And Gyn$16,339,593
- Leslie Bernstein · University Of Southern California$15,921,739
Research focus
Endometrial CarcinomaMalignant NeoplasmsCancer PatientObesityResponseClinical TrialsTumorWomanPharmaceutical PreparationsPathway InteractionsNon ObeseLinkEndometriumInsulin ResistanceDiabetes MellitusMetforminMouse ModelCancer TherapyCessation Of LifeTumorigenicMetabolicBiological MarkersEndometrial NeoplasmsMalignant - Descriptor
Grant awards (25)
Cancer Health Disparities SPORE in Endometrial Cancer$2,255,110
U54 · FY2025 · CA · contact PI
Project 2: Inter-Relationship of Disparities, the Microbiome, Innate Immune System and Immunotherapy Response in Endometrial Cancer$250,567
U54 · FY2025 · CA · contact PI
Enhancement training for the next generation of translational Ph.D. scientists$196,444
T32 · FY2025 · GM
Obesity-driven Metabolic and Molecular Biomarkers of Metformin Response in Endometrial Cancer$337,922
R37 · FY2024 · CA · contact PI
Enhancement training for the next generation of translational Ph.D. scientists$203,008
T32 · FY2024 · GM
Impact of Obesity on Immuno-Oncology Agents in Endometrial Cancer$172,653
R21 · FY2024 · CA · contact PI
Obesity-driven Metabolic and Molecular Biomarkers of Metformin Response in Endometrial Cancer$348,592
R37 · FY2023 · CA · contact PI
Enhancement training for the next generation of translational Ph.D. scientists$265,268
T32 · FY2023 · GM
Obesity-driven Metabolic and Molecular Biomarkers of Metformin Response in Endometrial Cancer$355,706
R37 · FY2022 · CA · contact PI
Impact of Obesity on Immuno-Oncology Agents in Endometrial Cancer$218,089
R21 · FY2022 · CA · contact PI
Obesity-driven Metabolic and Molecular Biomarkers of Metformin Response in Endometrial Cancer$355,706
R37 · FY2021 · CA · contact PI
Obesity-driven Metabolic and Molecular Biomarkers of Metformin Response in Endometrial Cancer$355,706
R37 · FY2020 · CA · contact PI
Interval exercise training as a therapy for endometrial cancer$168,381
R21 · FY2020 · CA
Obesity-driven Metabolic and Molecular Biomarkers of Metformin Response in Endometrial Cancer$345,034
R37 · FY2019 · CA · contact PI
Interval exercise training as a therapy for endometrial cancer$202,224
R21 · FY2019 · CA
Obesity-driven Metabolic and Molecular Biomarkers of Metformin Response in Endometrial Cancer$355,706
R37 · FY2018 · CA · contact PI
Inter-relationship between microbiota diversity, obesity and race in endometrial cancer$169,106
R21 · FY2018 · CA · contact PI
Inter-relationship between microbiota diversity, obesity and race in endometrial cancer$202,928
R21 · FY2017 · CA · contact PI
Metformin as a Novel Chemotheraeutic Strategy for the Treatment of Endometrial Ca$170,873
K23 · FY2014 · CA · contact PI
TRANSPORTERS IN METFORMIN TREATMENT OF ENDOMETRIAL HYPERPLASIA$73,720
R03 · FY2014 · CA
Metformin as a Novel Chemotheraeutic Strategy for the Treatment of Endometrial Ca$170,873
K23 · FY2013 · CA · contact PI
TRANSPORTERS IN METFORMIN TREATMENT OF ENDOMETRIAL HYPERPLASIA$76,000
R03 · FY2013 · CA
Metformin as a Novel Chemotheraeutic Strategy for the Treatment of Endometrial Ca$170,873
K23 · FY2012 · CA · contact PI
Metformin as a Novel Chemotheraeutic Strategy for the Treatment of Endometrial Ca$170,873
K23 · FY2011 · CA · contact PI
Metformin as a Novel Chemotheraeutic Strategy for the Treatment of Endometrial Ca$170,873
K23 · FY2010 · CA · contact PI